Celecoxib (Celebrex) is the safer choice for patients with supraventricular tachycardia
For patients with SVT requiring NSAID therapy, celecoxib should be preferred over meloxicam due to its lower cardiovascular risk profile and comparable safety in this cardiac population.
Cardiovascular Safety: The Critical Factor in SVT
The primary concern when selecting an NSAID for a patient with SVT is cardiovascular safety, as all NSAIDs can worsen hypertension, precipitate congestive heart failure, and increase the risk of thrombotic events 1. However, the evidence demonstrates important differences between these agents:
Celecoxib Shows Lower Cardiovascular Risk
Direct comparison data from Taiwan involving 9,602 long-term NSAID users found that celecoxib users had significantly lower hazard ratios for acute myocardial infarction (HR 0.78,95% CI 0.63-0.96) and stroke (HR 0.81,95% CI 0.70-0.93) compared to meloxicam users 2
A 2025 umbrella review confirmed that celecoxib's cardiovascular safety outcomes are generally similar to non-selective NSAIDs, with one meta-analysis showing lower cardiovascular mortality with celecoxib than with non-selective NSAIDs 3
Prescription-Event Monitoring data from England showed a 1.66-fold higher rate of cerebrovascular thromboembolic events with celecoxib compared to meloxicam 4, but this finding conflicts with the larger Taiwanese study and had very low absolute event rates (<0.5%)
Blood Pressure and Heart Failure Considerations
Both drugs can increase blood pressure by approximately 5 mm Hg 1, but the FDA label for celecoxib specifically warns about worsening hypertension and heart failure 5. Monitor blood pressure closely during initiation and throughout therapy with either agent 5. Avoid both drugs if the patient has decompensated heart failure 1.
Practical Prescribing Algorithm for SVT Patients
Step 1: Assess cardiovascular risk factors
- History of MI, stroke, or other thrombotic events in the past year increases risk 3-7 fold 2
- Presence of hypertension, heart failure, or other cardiac disease
- Concurrent use of anticoagulants or antiplatelet agents
Step 2: If NSAID is necessary, choose celecoxib
- Dose: 100-200 mg twice daily (use lowest effective dose) 5
- Duration: Shortest time needed 1
- The cardiovascular data favors celecoxib over meloxicam in patients with cardiac conditions 2
Step 3: Add gastroprotection if indicated
- Combine with PPI if age >65, history of GI bleeding, or concurrent anticoagulant use 1
- Celecoxib alone provides better GI safety than non-selective NSAIDs 3
Step 4: Monitor closely
- Blood pressure within 2 weeks of initiation 5
- Signs of heart failure (edema, dyspnea) 1
- Cardiovascular symptoms (chest pain, neurologic changes) 5
Important Caveats
Absolute Contraindications for Both Drugs
- Do not use immediately before or after cardiac bypass surgery 5
- Avoid in patients with decompensated heart failure 1
- Use extreme caution if concurrent anticoagulation (increases bleeding risk 3-6 fold) 1
The Cost Consideration
While meloxicam costs approximately $183 less per prescription than celecoxib 6, this cost savings should not override cardiovascular safety concerns in a patient with pre-existing cardiac arrhythmia.
Renal Safety
Both agents carry similar renal risks 1. Celecoxib does not decrease glomerular filtration rate more than other NSAIDs and may be associated with fewer renal adverse events 3, 7. Avoid both in patients with significant renal impairment.
Why Not Meloxicam?
Meloxicam is a "moderately selective" COX-2 inhibitor that partially inhibits COX-1 at higher doses 6, 8. While some sources suggest it represents a "golden mean" between GI and cardiovascular safety 8, the head-to-head data specifically shows worse cardiovascular outcomes compared to celecoxib in the population most relevant to your question 2.
The 2022 study showing similar GI bleeding and wound complications between meloxicam and celecoxib 6 was conducted in post-surgical orthopedic patients—a different population than SVT patients where cardiovascular risk is the primary concern.